Cost-effectiveness analysis of afatinib vs gefitinib in EGFR-Mutated population with advanced non-small-cell lung cancer

被引：0
|
作者：
Chouaid, Christos
De Pouvourville, Gerard
Laura, Luciani
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2017年 / 50卷
关键词：
D O I：
10.1183/1393003.congress-2017.PA2794
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA2794
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
    Aredo, Jacqueline, V
    Wakelee, Heather A.
    Neal, Joel W.
    Padda, Sukhmani K.
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 30
  • [32] A Single-Institution Experience of Afatinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
    Minemura, Hiroyuki
    Yokouchi, Hiroshi
    Hirai, Kenichiro
    Koizumi, Tatsuhiko
    Kanazawa, Kenya
    Tanino, Yoshinori
    Munakata, Mitsuru
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1230 - S1231
  • [33] Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
    Yuta Nio
    Hiroo Ishida
    Natsumi Matsumoto
    Sojiro Kusumoto
    Yutaro Kubota
    Takuya Tsunoda
    Yasutsuna Sasaki
    Ken-ichi Fujita
    BMC Pulmonary Medicine, 22
  • [34] Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
    Nio, Yuta
    Ishida, Hiroo
    Matsumoto, Natsumi
    Kusumoto, Sojiro
    Kubota, Yutaro
    Tsunoda, Takuya
    Sasaki, Yasutsuna
    Fujita, Ken-ichi
    BMC PULMONARY MEDICINE, 2022, 22 (01)
  • [35] Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer
    Cheng, Haiying
    Hosgood, H. Dean
    Deng, Lei
    Ye, Kenny
    Su, Christopher
    Sharma, Janaki
    Yang, Yuanquan
    Halmos, Balazs
    Perez-Soler, Roman
    CLINICAL LUNG CANCER, 2020, 21 (02) : 177 - 185
  • [36] Application of several machine learning algorithms for the prediction of afatinib treatment outcome in advanced-stage EGFR-mutated non-small-cell lung cancer
    Kim, Taeyun
    Lee, Sang Jin
    Jang, Tae-Won
    THORACIC CANCER, 2022, 13 (23) : 3353 - 3361
  • [37] Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
    Wan, Xiaomin
    Zeng, Xiaohui
    Peng, Liubao
    Peng, Ye
    Liu, Qiao
    Yi, Lidan
    Luo, Xia
    Deng, Qijian
    Tan, Chongqing
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [38] Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer
    Melosky, B.
    Banerji, S.
    Blais, N.
    Chu, Q.
    Juergens, R.
    Leighl, N. B.
    Liu, G.
    Cheema, P.
    CURRENT ONCOLOGY, 2020, 27 (02) : E146 - E155
  • [39] Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancer
    Lee, Victor H. F.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 4 - 6
  • [40] Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer
    Kimura, M.
    Yasue, F.
    Usami, E.
    Kawachi, S.
    Iwai, M.
    Go, M.
    Ikeda, Y.
    Yoshimura, T.
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (02) : 201 - 206
12345